ADGI Potential Neutralizing Activity Against Covid-19 Variants

NASDAQ:ADGI   Adagio Therapeutics, Inc
Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.

Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.

Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.

My price target is the $14.5 resistance.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.